Anastrozole

• CAT Number: A000973
• CAS Number: 120511-73-1
• Molecular Formula: C17H19N5
• Molecular Weight: 293.4
• Purity: ≥95%
• Target: Aromatase
• Solubility: 10 mM in DMSO
• Storage: -20°C
• IC50: 15 nM
• IUPAC Name: 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
• InChI: InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
• InChIKey: YBBLVLTVTVSKRW-UHFFFAOYSA-N
• SMILES: CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N

Anastrozole (CAS 120511-73-1), sold under the trade name Arimidex among others, is a medication used in addition to other treatments for breast cancer. Specifically it is used for hormone receptor-positive breast cancer. It has also been used to prevent breast cancer in those at high risk. It is taken by mouth.

Common side effects include hot flashes, altered mood, joint pain, and nausea. Severe side effects include an increased risk of heart disease and osteoporosis. Use during pregnancy is known to harm the baby. Anastrozole is in the aromatase-inhibiting family of medications. It works by blocking the creation of estrogen.

Reference

1: Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd LE, O/'Shaughnessy J, Parulekar WR, Liedke PER, Chen BE, Goss PE. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. Eur J Cancer. 2017 Dec 20;90:19-25. doi: 10.1016/j.ejca.2017.11.014. [Epub ahead of print] PubMed PMID: 29274617.
2: Morimoto Y, Sarumaru S, Oshima Y, Tsuruta C, Watanabe K. Joint symptoms associated with anastrozole and letrozole in patients with breast cancer: a retrospective comparative study. J Pharm Health Care Sci. 2017 Nov 7;3:25. doi: 10.1186/s40780-017-0095-6. eCollection 2017. PubMed PMID: 29177067; PubMed Central PMCID: PMC5688801.
3: Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. Ann Oncol. 2017 Nov 6. doi: 10.1093/annonc/mdx713. [Epub ahead of print] PubMed PMID: 29126161.
4: Monda V, Lupoli GA, Messina G, Peluso R, Panico A, Villano I, Salerno M, Sessa F, Marciello F, Moscatelli F, Valenzano A, Molino L, Lupoli R, Fonderico F, Tortora A, Pisano A, Ruberto M, Gabriella M, Cavaliere G, Trinchese G, Mollica MP, Cipolloni L, Cibelli G, Monda M, Lupoli G, Messina A. Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole. Front Pharmacol. 2017 Sep 12;8:632. doi: 10.3389/fphar.2017.00632. eCollection 2017. PubMed PMID: 28955236; PubMed Central PMCID: PMC5601069.
5: Boutas I, Pergialiotis V, Salakos N, Korou LM, Mitousoudis A, Kalampokas E, Deligeoroglou E, Gregoriou O, Perrea DN, Creatsas G, Kourkoulis S. Assessment of bone metabolism and biomechanical properties of the femur, following treatment with anastrozole and letrozole in an experimental model of menopause. Oncol Lett. 2017 Sep;14(3):3494-3502. doi: 10.3892/ol.2017.6596. Epub 2017 Jul 18. PubMed PMID: 28943895; PubMed Central PMCID: PMC5592877.
6: Sun X, Lv M, Wang B, Zhao S, Guo P, Wang S, Gu L, Chen X. Comparative pharmacokinetics study of anastrozole after single administration and combination with celecoxib. Xenobiotica. 2018 Mar;48(3):279-284. doi: 10.1080/00498254.2017.1298872. Epub 2017 Sep 14. PubMed PMID: 28906164.
7: Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5. PubMed PMID: 28874413.
8: Nave R, Klein S, Müller A, Chang X, Höchel J. Absence of Effect of Intravaginal Miconazole, Clindamycin, Nonoxynol-9, and Tampons on the Pharmacokinetics of an Anastrozole/Levonorgestrel Intravaginal Ring. J Clin Pharmacol. 2018 Jan;58(1):97-106. doi: 10.1002/jcph.984. Epub 2017 Aug 7. PubMed PMID: 28783867.
9: Klapko O, Ghoulam E, Jakate S, Eswaran S, Usha L. Anastrozole-induced Autoimmune Hepatitis: A Rare Complication of Breast Cancer Therapy. Anticancer Res. 2017 Aug;37(8):4173-4176. PubMed PMID: 28739702.
10: Ding H, Fang L, Xin W, Tong Y, Zhou Q, Huang P. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12733. Epub 2017 Jul 3. PubMed PMID: 28675545.